

mirabegron for extended-release oral suspension (MYBETRIQ GRANULES)

Diagnoses Considered for Coverage:

- Treatment of overactive bladder
- Neurogenic detrusor overactivity

Coverage Criteria:

1. For diagnoses considered for coverage:

- Dose does not exceed FDA label maximum, **and**
- Inadequate response, intolerable side effect, or contraindication to oxybutynin

Coverage Duration: one year

References:

1. Myrbetriq Granules. Prescribing Information. Astellas Pharma US, Inc. Northbrook, IL. 3.2021

Effective Date: 6/1/2022